THE JAK2V617F POINT MUTATION INCREASES THE OSTEOCLAST FORMING ABILITY OF MONOCYTES IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS AND MAKES THEIR OSTEOCLASTS MORE SUSCEPTIBLE TO JAK2 INHIBITION. Mediterr J Hematol Infect Dis [Internet]. 2018 Oct. 27 [cited 2026 May 5];10(1):e2018058. Available from: https://www.mjhid.org/mjhid/article/view/2018.058